Arcturus Therapeutics Holdings/$ARCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
Ticker
$ARCT
Sector
Health
Primary listing
Employees
175
Headquarters
Website
ARCT Metrics
BasicAdvanced
$325M
-
-$2.52
2.37
-
Price and volume
Market cap
$325M
Beta
2.37
52-week high
$24.57
52-week low
$8.04
Average daily volume
431K
Financial strength
Current ratio
5.643
Quick ratio
4.686
Long term debt to equity
16.678
Total debt to equity
18.249
Profitability
EBITDA (TTM)
-78.642
Gross margin (TTM)
-22.83%
Net profit margin (TTM)
-47.47%
Operating margin (TTM)
-57.13%
Effective tax rate (TTM)
0.54%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-13.67%
Return on equity (TTM)
-27.40%
Valuation
Price to revenue (TTM)
2.256
Price to book
1.39
Price to tangible book (TTM)
1.39
Price to free cash flow (TTM)
-3.607
Free cash flow yield (TTM)
-27.73%
Free cash flow per share (TTM)
-3.322
Growth
Revenue change (TTM)
15.38%
Earnings per share change (TTM)
-37.27%
3-year revenue growth (CAGR)
110.17%
3-year earnings per share growth (CAGR)
-30.56%
What the Analysts think about ARCT
Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.
ARCT Financial Performance
Revenues and expenses
ARCT Earnings Performance
Company profitability
ARCT News
AllArticlesVideos
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Business Wire·2 weeks ago
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
Business Wire·1 month ago
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcturus Therapeutics Holdings stock?
Arcturus Therapeutics Holdings (ARCT) has a market cap of $325M as of August 08, 2025.
What is the P/E ratio for Arcturus Therapeutics Holdings stock?
The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of August 08, 2025.
Does Arcturus Therapeutics Holdings stock pay dividends?
No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of August 08, 2025.
When is the next Arcturus Therapeutics Holdings dividend payment date?
Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.